ALKERMES | ALKS - Assets


ALKERMES reported $4.26B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
ALKERMES USD 4.26B 1.77B Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Malin Corporation EUR 198.5M 70.1M Dec/2024
Merck USD 128.68B 8.18B Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Otsuka Holdings JPY 4.21T 11.63B Mar/2026
Ovoca Bio EUR 1.66M 9.75M Jun/2025
Pfizer USD 207.62B 542M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026